weight loss injections retatrutide Phase III retatrutide study demonstrates

GLP-1 medications can play a transformative role in improving metabolic health by helping to regulate blood sugar and promote feelings of fullness

The association between percentage BMI change and rs10305420 was replication significant, with directionality consistent with that observed in the 23andMe cohort ( P = 0.001

For more on specific treatments, see our Weight Loss Service page.

placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes

40,107 The pathophysiology of diabetic diarrhoea is complex and has conventionally been regarded as a manifestation of autonomic neuropathy

GLP-1 receptors are distributed throughout multiple organ systems, including the pancreas, gastrointestinal tract, cardiovascular system, and importantly, the central nervous system